🔗 Visit the ClinicalTrials.gov page for NCT02511184
| Rank | Title | Journal | Year | PubWeight™‹?› |
|---|---|---|---|---|
| 1 | Checkpoint inhibitors in lung cancer: latest developments and clinical potential. | Ther Adv Med Oncol | 2016 | 0.96 |
| 2 | Mutation testing for directing upfront targeted therapy and post-progression combination therapy strategies in lung adenocarcinoma. | Expert Rev Mol Diagn | 2016 | 0.80 |
| 3 | FGFR1 inhibition in lung squamous cell carcinoma: questions and controversies. | Cell Death Discov | 2015 | 0.80 |
| 4 | Recent Advances in Immunotherapy in Metastatic NSCLC. | Front Oncol | 2016 | 0.79 |
| 5 | Combining targeted therapy with immunotherapy. Can 1+1 equal more than 2? | Semin Immunol | 2016 | 0.78 |
| 6 | Oncogenic kinase fusions: an evolving arena with innovative clinical opportunities. | Oncotarget | 2016 | 0.76 |
| 7 | Personalized treatment in advanced ALK-positive non-small cell lung cancer: from bench to clinical practice. | Onco Targets Ther | 2016 | 0.75 |